-
Pluristem Therapeutics Announces Receipt Of 2 Key Cell Therapy Patents In Japan; Shares Tick Higher
Wednesday, April 13, 2016 - 8:51am | 305Read More...Shares of Pluristem Therapeutics Inc. (NASDAQ: PSTI), a bio-therapeutics company focusing on the treatment of multiple ischemic and inflammatory conditions, were trading higher by more than 7 percent early Wednesday morning after the company announced it was granted two key cell therapy patents....
-
Shares Of Pluristem Therapeutics Surging Following Receipt Of Orphan Drug Designation
Thursday, December 31, 2015 - 11:20am | 191Read More...Shares Pluristem Therapeutics Inc. (NASDAQ: PSTI), a biotherapeutics company that develops off-the-shelf allogeneic cell therapy products, surged higher by more than 16 percent on Thursday. Pluristem Therapeutics announced on Thursday that the U.S. Food and Drug Administration (FDA) granted the...
-
Oppenheimer Maintains Outperform Rating On Pluristem Therapeutics
Thursday, June 2, 2011 - 9:18am | 151Read More...According to Oppenheimer, Pluristem Therapeutics (NASDAQ: PSTI) Outperform rating is maintained. Oppenheimer said that yesterday, Aastrom Biosciences (ASTM, $3.04, Not Rated) reported top-line results for its Phase II study called RESTORE-CLI. “The trial investigated administration of expanded...
